Showing all entries tagged with »rare diseases«
February 27, 2025
Building on a previous blog on the need to reduce medicine approval timelines, it is imperative that all Orphan Medicinal Products (OMPs) be eligible for consideration under the EMA’s Priority Medicines (PRIME) scheme as part of the Revised General Pharmaceutical… read more
August 24, 2023
In this article, Michael N. Abrams and Alexander Natz discuss the current policy initiatives from Europe and the U.S., similarities between them, and implications for the pharmaceutical sector and their standing in a competitive global market. For years, lawmakers have… read more
July 26, 2023
Digitalization is becoming an increasingly more important part of the future of healthcare. It provides an unprecedented opportunity as recent developments in digital innovative technologies such as Artificial Intelligence (AI), machine learning (ML) in medical devices and algorithmic capabilities can… read more
May 3, 2023
In this guest blog, Toon Digneffe, EUCOPE Board Member & Head of Public Affairs and Partnerships – Europe & Canada at Takeda, reflects on the EU Pharmaceutical Package and highlights the importance of multi-stakeholder partnerships to build a sustainable rare… read more
February 22, 2023
There is still a way to go to tackle the 95% of rare diseases without treatments and Rare Disease Day 2023 serves as an important reminder of the arduous tasks ahead required to design a brighter future for European people… read more